UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 219

Sortiert nach

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2015-11, Vol.373 (19), p.1803-1813

2015

Link zum Volltext

Verfügbarkeit prüfen

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

Annals of oncology, 2018-11, Vol.29 (11), p.2208-2213

2018

Link zum Volltext

Verfügbarkeit prüfen

Editorial: Immune checkpoint inhibitors in renal cell carcinoma

Frontiers in oncology, 2023-04, Vol.13, p.1203463-1203463

2023

Link zum Volltext

Verfügbarkeit prüfen

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

European urology, 2017-12, Vol.72 (6), p.962-971

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

The New England journal of medicine, 2012-06, Vol.366 (26), p.2455-2465

2012

Link zum Volltext

Verfügbarkeit prüfen

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

Journal of clinical oncology, 2021-09, Vol.39 (26), p.2914-2925

2021

Link zum Volltext

Verfügbarkeit prüfen

Toward eliminating HLA class I expression to generate universal cells from allogeneic donors

Blood, 2013-08, Vol.122 (8), p.1341-1349

2013

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip system

Neoplasia (New York, N.Y.), 2023-12, Vol.46, p.100948-100948, Article 100948

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial

Journal for immunotherapy of cancer, 2022-02, Vol.10 (2), p.e003844

2022

Link zum Volltext

Verfügbarkeit prüfen

PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence

OncoTargets and therapy, 2014-01, Vol.7 (default), p.1349-1359

Tykodi, Scott S

2014

Link zum Volltext

Verfügbarkeit prüfen

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Journal for immunotherapy of cancer, 2019-02, Vol.7 (1), p.49-7, Article 49

2019

Link zum Volltext

Verfügbarkeit prüfen

Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma

Human vaccines & immunotherapeutics, 2021-07, Vol.17 (7), p.1882-1896

2021

Link zum Volltext

Verfügbarkeit prüfen

Thyroid-Like Follicular Renal Cell Carcinoma Arising Within Benign Mixed Epithelial and Stromal Tumor

International journal of surgical pathology, 2020-02, Vol.28 (1), p.80-86

2020

Link zum Volltext

Verfügbarkeit prüfen

Associating sleep problems with advanced cancer diagnosis, and immune checkpoint treatment outcomes: a pilot study

Supportive care in cancer, 2022-05, Vol.30 (5), p.3829-3838

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

Journal for immunotherapy of cancer, 2022-12, Vol.10 (12), p.e005445

2022

Link zum Volltext

Verfügbarkeit prüfen

Signaling crosstalk between tumor endothelial cells and immune cells in the microenvironment of solid tumors

Frontiers in cell and developmental biology, 2024-04, Vol.12, p.1387198-1387198

2024

Link zum Volltext

Verfügbarkeit prüfen

Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricted expanded clones with unique phenotypes

Frontiers in oncology, 2022-09, Vol.12, p.952252-952252

2022

Link zum Volltext

Verfügbarkeit prüfen

Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era

Urology (Ridgewood, N.J.), 2015-08, Vol.86 (2), p.262-268

2015

Link zum Volltext

Verfügbarkeit prüfen

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma

Cancer medicine (Malden, MA), 2022-08, Vol.11 (16), p.3106-3114

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial

BMJ open, 2022-09, Vol.12 (9), p.e058396-e058396

2022

Link zum Volltext

Verfügbarkeit prüfen

Antigen Produced by Splicing of Noncontiguous Peptides in the Reverse Order

Science (American Association for the Advancement of Science), 2006-09, Vol.313 (5792), p.1444-1447

2006

Link zum Volltext

Verfügbarkeit prüfen

Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab

Journal for immunotherapy of cancer, 2020-12, Vol.8 (2), p.e001591

2020

Link zum Volltext

Verfügbarkeit prüfen

Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214

Annals of oncology, 2018-10, Vol.29, p.viii309-viii310

2018

Link zum Volltext

Verfügbarkeit prüfen

KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)

Annals of oncology, 2018-10, Vol.29, p.viii307-viii307

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 219

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(202)
Mit Volltextzugriff
(206)

Publikationsform

Artikel
(217)
Dissertationen
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(102)
Life Sciences & Biomedicine
(66)
Humans
(51)
Oncology
(44)
Chemistry
(39)
Physical Sciences
(33)
Immunotherapy
(29)
Chemistry, Multidisciplinary
(26)
Male
(24)
Renal Cell Carcinoma
(24)
Kidney Cancer
(22)
Social Sciences
(22)
Education & Educational Research
(21)
Education, Scientific Disciplines
(21)
Female
(21)
Carcinoma, Renal Cell - Drug Therapy
(18)
Kidney Neoplasms - Drug Therapy
(18)
Adult
(17)
Metastasis
(17)
Middle Aged
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

Editorial: Immune checkpoint inhibitors in renal cell carcinoma

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

Toward eliminating HLA class I expression to generate universal cells from allogeneic donors

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip system

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial

PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma

Thyroid-Like Follicular Renal Cell Carcinoma Arising Within Benign Mixed Epithelial and Stromal Tumor

Associating sleep problems with advanced cancer diagnosis, and immune checkpoint treatment outcomes: a pilot study

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

Signaling crosstalk between tumor endothelial cells and immune cells in the microenvironment of solid tumors

Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricted expanded clones with unique phenotypes

Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial

Antigen Produced by Splicing of Noncontiguous Peptides in the Reverse Order

Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab

Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214

KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)

Suchergebnisse filtern